Allergies +51%. Vitamin D, an elixir to combat asthma and hay fever

Updated and contextualized version of an article originally published on May 10, 2021
The article retains its original focus by presenting it through a scholarly and accessible perspective, supported by verifiable references.

Authors

• Dr. A. Colonnese – Nutrition biologist
• Roberto Panzironi –Independent researcher 

Note editoriali

• First publication: May 10, 2021
• Last update: April 18, 2026
• Version: 2026 narrative revision  

In brief

• Vitamin D is an immune modulator with biological plausibility to influence respiratory infections and certain allergic manifestations.
• Clinical studies are heterogeneous: some meta-analyses show a reduction in asthma exacerbations or respiratory infections in specific subgroups; targeted trials do not always confirm a uniform benefit. [1][2][6]
• Observational evidence linking low 25(OH)D levels to asthma, rhinitis, or dermatitis is abundant, but genetic studies do not support a clear causal relationship. [4]
• In practice, controlling vitamin D levels makes sense as part of the nutritional and preventive picture, but it is not currently a standalone cure for asthma or hay fever.

Abstract: what does science say?

Vitamin D is a pro-hormone produced by the skin with sun exposure and available in foods and supplements. Its action goes beyond bone metabolism: experimental literature indicates roles in regulating the immune response and modulating inflammation. Clinical evidence is mixed. Randomized clinical trials (RCTs) aimed at preventing asthma exacerbations or improving allergic symptoms show variable results depending on age, baseline 25-hydroxyvitamin D (25[OH]D) levels, dosage, and duration of administration. Recent meta-analyses and reviews highlight that supplementation can reduce the risk of certain events (e.g., exacerbations in pediatric subgroups or respiratory infections in those who are deficient), but the effect is not universal and depends on the context. There are also genetic data (Mendelian randomization) that do not support a strong causal effect of vitamin D on the risk of atopic diseases, which suggests that the observed association may be influenced by confounding factors or indirect effects. In summary: biological plausibility and some positive signals, but no definitive proof that vitamin D is a universal "elixir" for asthma and hay fever; the benefit is likely limited to people with documented deficiency or specific clinical contexts.

What it means in practice

For those living with asthma, allergic rhinitis, or atopic dermatitis, the practical message is one of caution and general prevention. First, measuring and correcting a documented vitamin D deficiency is part of good nutritional practices and can be useful for bone health and, in some cases, for reducing recurrent respiratory events. Randomized trials and systematic reviews show heterogeneous results: a clinical study in high-risk children did not demonstrate a reduction in time to exacerbations with high-dose supplementation, while larger meta-analyses suggest a possible decrease in exacerbations in specific pediatric subgroups. [1][2]

Second, it is not advisable to use vitamin D as a substitute for effective and certified therapies for asthma (inhalers, maintenance therapy) or for rhinitis and allergen-specific immunotherapy. Some evidence indicates that vitamin D can act as an adjuvant in particular clinical conditions (for example, in children with marked deficiency), but the choice of dosage, form (cholecalciferol vs calcifediol), and duration requires medical evaluation. [3][7]

Evidence Details

Asthma and exacerbations

Clinical studies on the use of vitamin D as an add-on to standard therapy in asthma have yielded divergent results. A randomized trial in children with 25(OH)D levels below the cut-off showed no significant improvement over time in exacerbations compared to placebo, indicating that the effect is not automatic in all clinical groups. [1] On the other hand, reviews and meta-analyses aggregating multiple trials suggest that supplementation may reduce the frequency of exacerbations in some pediatric subgroups or in subjects with severe deficiency; the magnitude of the effect varies greatly depending on inclusion criteria, dosage, and duration. [2]

Allergic rhinitis and hay fever

For allergic rhinitis, clinical evidence comes from a few RCTs and recent systematic reviews. Analysis of available trials shows a possible reduction in symptoms and the need for medication in some studies, but methodological heterogeneity is high (different doses, co-treatments, participant ages). Some more recent reviews indicate a favorable but not conclusive signal, and emphasize the need for larger and more uniform trials to define who might truly benefit. [3][4]

Atopic dermatitis and other atopic manifestations

Clinical studies on patients with atopic dermatitis report clinical improvements in some small-scale trials; other trials show no significant effects. A pediatric RCT evaluated supplementation and showed mixed results: some biomarkers and symptoms may improve in subgroups (e.g., initial deficiency), but large-scale confirmations are lacking. The literature suggests that correcting a deficiency is reasonable in AD patients, while acknowledging limitations in generalizability. [5]

Recurrent Respiratory Infections

One of the strongest pieces of evidence concerns the prevention of respiratory infections: an individual participant data meta-analysis showed an overall reduction in episodes of respiratory infection with vitamin D supplementation, with a greater effect in those who were severely deficient and with regular administration (not in single, widely spaced doses). This result is relevant because superimposed viral infections are often a trigger for asthma exacerbations. [6]

Key takeaways

• Vitamin D has biological plausibility as an immune modulator, but it is not a miracle cure for asthma or rhinitis.
• The most consistent clinical benefit emerges for the prevention of certain respiratory infections and for the reduction of exacerbations in specific pediatric subgroups with documented deficiency. [2][6]
• Genetic studies of the Mendelian randomization type do not support a strong causal effect of 25(OH)D on the risk of atopy, which calls for caution in interpreting observational associations. [7]
• The decision to measure or supplement vitamin D must be individual, based on blood levels, clinical status, and medical evaluation.

Limitations of Evidence

It is important to distinguish between study types and methodological limitations. Observational studies show associations between low levels of 25(OH)D and a higher prevalence or severity of certain allergic conditions; however, such studies do not establish causality and can be influenced by confounders (lifestyle, sun exposure, obesity, socioeconomic status). Randomized controlled trials (RCTs) are the gold standard, but many RCTs on the subject have limited sample sizes, heterogeneous criteria (different doses, forms of vitamin D, and duration), and often do not stratify by baseline 25(OH)D levels. Meta-analyses can combine these data but remain sensitive to heterogeneity and the risk of bias. Finally, genetic studies (Mendelian randomization) provide an additional lens: if there is no causal genetic relationship, the large-scale preventive impact of supplementation to reduce atopic diseases might be limited. [7]

Editorial conclusion

Research on vitamin D, asthma, and hay fever has made significant progress: today we have more quality studies than in the past and systematic reviews that highlight interesting signals, especially in subjects with deficiency. However, there is no definitive proof that vitamin D eradicates or generally prevents allergies or asthma. For the public, the practical recommendation remains: evaluate vitamin D status if indicated, correct certified deficiencies, and consider supplementation only after consulting with a doctor. The goal of the healthcare system and prevention remains an integrated approach: a healthy lifestyle, environmental control of allergens, approved therapies, and, when necessary, proper nutritional support documented by tests. Science continues to investigate which subgroups may benefit most and what the optimal dose, form, and duration are.

Editorial note

Article updated according to criteria of transparency, source control, and divulgative clarity. The update included systematic reviews, clinical trials, and genetic studies selected for clinical relevance and verifiability. The content is for informational purposes only and does not replace an individual clinical evaluation.

SCIENTIFIC RESEARCH

1. Forno E, et al. Effect of Vitamin D3 Supplementation on Severe Asthma Exacerbations in Children With Asthma and Low Vitamin D Levels: The VDKA Randomized Clinical Trial. JAMA. 2020. https://doi.org/10.1001/jama.2020.12384
2. Hao M, Xu R, Luo N, et al. The Effect of Vitamin D Supplementation in Children With Asthma: A Meta-Analysis. Front Pediatr. 2022. https://doi.org/10.3389/fped.2022.840617
3. Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017. https://doi.org/10.1136/bmj.i6583
4. Manousaki D, et al. Vitamin D levels and susceptibility to asthma, elevated immunoglobulin E levels, and atopic dermatitis: a Mendelian randomization study. PLoS Med. 2017. https://doi.org/10.1371/journal.pmed.1002294
5. Li Q, Zhou Q, Zhang G, et al. Vitamin D Supplementation and Allergic Diseases during Childhood: A Systematic Review and Meta-Analysis. Nutrients. 2022;14(19):3947. https://doi.org/10.3390/nu14193947
6. Vitamin D Level and Supplementation in Pediatric Atopic Dermatitis: A Randomized Controlled Trial. J Cutan Med Surg. 2019. https://doi.org/10.1177/1203475418805744
7. Calcifediol for Use in Treatment of Respiratory Disease. Nutrients. 2022;14(12):2447. https://doi.org/10.3390/nu14122447
8. Kawada K, Sato C, Ishida T, et al. Vitamin D Supplementation and Allergic Rhinitis: A Systematic Review and Meta-Analysis. Medicina. 2025;61(2):355. https://doi.org/10.3390/medicina61020355

If you wish, we can produce an extended version with key extracts from the studies (summarized abstracts) and the complete DOI checklist for each reference.